Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
AlgiPharma AS operates a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The current USPTO workload for this entity consists of 1 pending office action. This specific matter is handled by 1 distinct examiner, BERRY, LAYLA D, who is the only examiner noted in the profile. The prosecution activity is confined to a distinct art unit, indicating a narrow technical focus for the company's current claims. BERRY, LAYLA D is the busiest examiner, managing the busiest examiner pending action.
Practitioners should note that the presence of a pending office action in a distinct art unit allows for a very targeted prosecution strategy. Because the workload is not spread across multiple examiners, the company can focus on the specific examination style of BERRY, LAYLA D. This concentration within the Biotechnology & Pharmaceuticals sector suggests that the intellectual property is currently focused on a singular specialized application. Navigating the assigned art unit requires understanding the specific prior art and procedural trends prevalent in that group.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BERRY, LAYLA D | 1 | 66.0% | +9.0% |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17596741 | USE OF ALGINATE OLIGOMERS IN THE ANTICOAGULATION THERAPY OF SUBJECTS AT RISK OF BLOOD CLOTS WHICH HAVE AN ABNORMALLY DENSE MICROSTRUCTURE | BERRY, LAYLA D | 1693 | §103Other | Final Rejection | 5d overdue | Pending | Dec 16, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial